Other meanings of Positron emission tomography
MEDICAL IMAGING
Positron emission tomography is a medical imaging technique using positron-emitting radiotracers to map physiological and biochemical activity in the body. It complements anatomical methods such as computed tomography and magnetic resonance imaging by showing how tissues function, not only what they look like.
Positron emission tomography produces images by detecting pairs of photons created when a positron meets an electron. A radiotracer containing a positron-emitting radionuclide is injected, inhaled, or occasionally administered by another route; after traveling a short distance, each positron annihilates with an electron and produces two 511-keV photons moving in nearly opposite directions. A ring of detectors records coincident photons and reconstructs their likely origin. The resulting images represent tracer distribution over time. Fluorine-18 fluorodeoxyglucose, or 18F-FDG, is widely used because many cancers and active inflammatory tissues consume glucose rapidly, although PET can also study blood flow, oxygen use, neurotransmitter receptors, and other molecular processes.1
PET examinations require preparation that matches the tracer and the clinical question. For an 18F-FDG study, patients commonly fast for several hours and have blood glucose checked; strenuous exercise before scanning can alter muscular uptake.2 After administration, a distribution period allows the tracer to reach target tissues, followed by imaging while the patient remains still. PET is frequently combined with computed tomography in a single PET/CT examination, allowing metabolic abnormalities to be localized against detailed anatomy. Images may be assessed visually and with standardized uptake values, but uptake is not synonymous with cancer: infection, inflammation, healing, and normal organs can also accumulate tracer. Interpretation therefore depends on symptoms, anatomy, timing, and clinical history.
PET is especially valuable when biological activity changes before anatomy becomes clearly abnormal. In oncology, it assists with staging, treatment response assessment, recurrence evaluation, and selection of some therapies; 18F-FDG PET/CT is used across several cancers, though its performance varies by tumor type. Neurology uses specialized tracers to investigate patterns of brain metabolism and selected protein deposits, while cardiology can use PET to assess myocardial perfusion and viability.1 The technique has limitations: spatial resolution is lower than that of many structural scans, some tumors show little FDG uptake, and small lesions may be obscured by motion or nearby physiological activity. Radiation exposure comes from both the radiotracer and, in PET/CT, the CT component, so examinations are chosen when expected benefit outweighs risk.
PET depends on a time-sensitive supply chain because many radionuclides decay rapidly. Fluorine-18 has a half-life of about 110 minutes, whereas carbon-11, oxygen-15, and nitrogen-13 decay much faster; centers using these short-lived nuclides generally need an on-site or nearby cyclotron. This constraint helped drive the development of regional radiopharmacies and automated synthesis systems. PET is also used in research to quantify receptor occupancy, neurotransmitter release, and drug distribution, not merely to produce diagnostic pictures. Hybrid PET/MRI can combine molecular information with high-contrast soft-tissue imaging while reducing ionizing radiation from the anatomical component, although cost, complexity, attenuation correction, and limited availability restrict its routine use.1 Radiotracer choice remains central: the scan answers a biological question only to the extent that the tracer measures the relevant process.
Clinical interpretation and radiotracer selection are determined by qualified nuclear-medicine and radiology professionals; local protocols vary by indication and facility.
Help improve the encyclopedia. Reports go straight to the site manager.